RTP Mobile Logo
Optimizing Biomarker-Based Decision-Making for Patients with Non-Small Cell Lung Cancer with EGFR Mutations or with Other Oncogene-Addicted Lung Cancers — Session 1 (Webinar Video Proceedings)
Released December 2021

Featuring perspectives from Drs Marc Ladanyi, Andrew McKenzie and Joel Neal. Published December 14, 2021. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of lung cancer.


    • Recognize the spectrum of potentially targetable genomic alterations occurring in non-small cell lung cancer (NSCLC), and identify patients appropriate for targeted therapy by assessing the correlation between specific abnormalities and response to specific agents.
    • Evaluate the various oncogenic alterations identifiable in the epidermal growth factor receptor (EGFR) tyrosine kinase domain, and determine how they might predict potential response or lack thereof to EGFR-directed therapies.
    • Appreciate available Phase III findings supporting the efficacy of adjuvant osimertinib for EGFR mutation-positive NSCLC after complete resection, and identify patients appropriate for treatment with this recently FDA-approved strategy.
    • Evaluate available clinical trial findings supporting the FDA approval of amivantamab for patients with locally advanced or metastatic NSCLC and an EGFR exon 20 insertion mutation, and personalize management recommendations for individuals who might benefit from treatment with this novel compound.
    • Describe mechanisms of tumor resistance to EGFR tyrosine kinase inhibitors, and discern how available and investigational therapies can be optimally employed in the protocol and nonresearch care of patients with progressive disease with EGFR mutations.
    • Convey the clinical relevance of a positive ROS1 mutation test result to appropriate patients with NSCLC, appreciating available clinical research findings with approved and investigational agents demonstrating efficacy in these individuals.
    • Assess available research with approved RET inhibitors, and use this information to guide clinical care and protocol opportunities for patients with newly diagnosed or progressive NSCLC harboring RET abnormalities.
    • Recognize emerging findings with investigational HER2-directed therapies for advanced NSCLC with HER2 overexpression or mutation, and appropriately refer patients for clinical trials.
    • Recall other oncogenic pathways (eg, ALK, MET, NTRK, BRAF) mediating the growth of tumors in unique subsets of patients, and consider published and emerging data with commercially available and experimental agents exploiting these targets.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Marc Ladanyi, MD
    Chief, Molecular Diagnostics Service
    William J Ruane Chair in Molecular Oncology
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Janssen Biotech Inc, Lilly, Paige AI, Takeda Pharmaceuticals USA Inc; Contracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Elevation Oncology, Helsinn Healthcare SA, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merus BV.

    Andrew J McKenzie, PhD
    Director, Personalized Medicine
    Scientific Director, Genospace
    Sarah Cannon
    Nashville, Tennessee

    No relevant conflicts of interest to disclose.

    Joel W Neal, MD, PhD
    Associate Professor of Medicine
    Division of Oncology, Department of Medicine
    Stanford Cancer Institute
    Stanford University
    Palo Alto, California

    Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Calithera Biosciences, Exelixis Inc, Genentech, a member of the Roche Group, Iovance Biotherapeutics, Jounce Therapeutics, Lilly, Natera Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, Adaptimmune, Boehringer Ingelheim Pharmaceuticals Inc, Exelixis Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Janssen Biotech Inc, Merck, Nektar, Novartis, Takeda Pharmaceuticals USA Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Blueprint Medicines and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

    Release date: December 2021
    Expiration date: December 2022

Acknowledge and close

Watch video
(WIFI is recommended for best performance):